Historically dubbed the “love drug” for its ability to induce sensual feelings and pro-social behaviour, MDMA is now being researched for a number of social and...
Dalriada will be leveraging atai Life Science’s newly launched Invyxis platform to establish and rapidly advance a pipeline of new chemical entities (NCEs) in mental health.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
Mydecine has signed a Letter of Intent (LOI) with The Newly Institute to provide psychedelic-assisted psychotherapy to patients for Health Canada’s Special Access Program.
The application is for a clinical trial that intends to test the psilocybin extract for bioavailability and tolerability on 20 healthy volunteers.
The lion’s mane mushroom has a long and complex history of being used as a supplement as part of a healthy diet.
The world’s first controlled study exploring the use of ketamine-assisted psychotherapy for the treatment of alcohol use disorder (AUD) has shown positive results.
A new collaboration is aiming to develop psychedelic medicines to address the unique needs of people living with a variety of mental health conditions.
Return Health is exploring psychedelic derivatives for the treatment of dementia.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
